

# Breast Cancer Lung Metastasis Requires Expression of Chemokine Receptor CCR4 and Regulatory T Cells

Purevdorj B. Olkhanud,<sup>1</sup> Dolgor Baatar,<sup>1</sup> Monica Bodogai,<sup>1</sup> Fran Hakim,<sup>3</sup> Ronald Gress,<sup>3</sup> Robin L. Anderson,<sup>2</sup> Jie Deng,<sup>1</sup> Mai Xu,<sup>1</sup> Susanne Briest,<sup>4</sup> and Arya Biragyn<sup>1</sup>

<sup>1</sup>Laboratory of Immunology, National Institute on Aging, Baltimore, Maryland; <sup>2</sup>Cancer Biology Laboratory, Peter MacCallum Cancer Centre, Melbourne, Australia; <sup>3</sup>Experimental Transplantation and Immunology Branch, Bethesda, Maryland; and <sup>4</sup>Breast Cancer Center, University of Leipzig, Leipzig, Germany

## Abstract

**Cancer metastasis is a leading cause of cancer morbidity and mortality. More needs to be learned about mechanisms that control this process. In particular, the role of chemokine receptors in metastasis remains controversial. Here, using a highly metastatic breast cancer (4T1) model, we show that lung metastasis is a feature of only a proportion of the tumor cells that express CCR4. Moreover, the primary tumor growing in mammary pads activates remotely the expression of TARC/CCL17 and MDC/CCL22 in the lungs. These chemokines acting through CCR4 attract both tumor and immune cells. However, CCR4-mediated chemotaxis was not sufficient to produce metastasis, as tumor cells in the lung were efficiently eliminated by natural killer (NK) cells. Lung metastasis required CCR4<sup>+</sup> regulatory T cells (Treg), which directly killed NK cells using  $\beta$ -galactoside-binding protein. Thus, strategies that abrogate any part of this process should improve the outcome through activation of effector cells and prevention of tumor cell migration. We confirm this prediction by killing CCR4<sup>+</sup> cells through delivery of TARC-fused toxins or depleting Tregs and preventing lung metastasis.** [Cancer Res 2009;69(14):5996–6004]

## Introduction

The formation of metastatic colonies is a nonrandom process that starts early, during the growth of the primary tumor. In analogy with immune cells, tumor dissemination is presumed to require chemokine receptors. To date, expression of chemokine receptors were associated with cancer metastases, such as CXCR4, CCR7, and CCR10 in breast cancer (1) and CCR6, CCR7, CXCR5, and CX3CR1 in pancreatic, gastric, prostate, and non-small cell lung carcinoma cancers (2). Among them, CXCR4 seems to be a major metastasis-regulating receptor (see ref. 3) that uses the lymph node trafficking network of hematopoietic progenitors and endothelial cells (1, 4). Despite this, a direct role for chemokine receptors in mediating metastasis has not been defined, as the expression of chemokine receptors on the surface of tumors is rarely shown and difficult to confirm. Even for a widely used metastasis model, such as mouse mammary 4T1 carcinoma, the

role of chemokine receptors has not been confirmed. The 4T1 tumor mimics human breast cancer in several ways; it readily and spontaneously metastasizes to lung, lymph nodes, liver, bone, and other sites after implantation into the mammary pad of immune competent BALB/c mice (5). Metastasis of 4T1 tumor was mostly associated with a tumor-induced suppressive microenvironment and myeloid-derived suppressive cells (MDSC; Gr1<sup>+</sup> CD11b<sup>+</sup>; refs. 6–8). It seems that 4T1 tumor activates and expands these cells through production of granulocyte macrophage colony-stimulating factor (GM-CSF; refs. 8, 9) to impair antitumor T-cell function directly (8) or indirectly through the development of regulatory T cells (Treg; ref. 10). Tregs are a specialized subset of CD4<sup>+</sup> T cells that control peripheral tolerance to self-antigen and alloantigen (11). CCR4<sup>+</sup> Tregs have been shown to infiltrate human tumors and suppress antitumor activity of tumor-infiltrating effector T cells (12–15). Consequently, Tregs are presumed to support metastasis through inhibition of antitumor T-cell immune responses.

Chemokines TARC/CCL17 and MDC/CCL22 control homing of CCR4-expressing immune cells into lungs and skin to elicit protective pulmonary responses to pathogens. They recruit Th2 type CD4<sup>+</sup> T cells (16), Tregs (17, 18), and some interleukin 2 (IL-2)-activated natural killer (NK) cells, iNKT cells, and B cells (19–21). An aberrant expression of TARC or MDC is often associated with allergic diseases causing massive infiltration of Th2 type CD4<sup>+</sup> T cells (16, 22). Interestingly, we have observed that lungs of mice with 4T1 tumor growing in mammary glands secreted significant amounts of TARC. This has led us to hypothesize that 4T1 cells may express CCR4 and migrate to lungs the same way as CCR4<sup>+</sup> immune cells. Utilizing various tools, including a TARC-fused toxin (that we developed), which specifically kills CCR4<sup>+</sup> cells (17, 23), we show that CCR4 is expressed on a proportion of tumor cells that chemotax to TARC and metastasize to lung. However, despite this inherent capacity of the tumor to metastasize, lung metastasis required additional help from CCR4<sup>+</sup> Tregs. We show that Tregs neutralize antimetastatic effect of NK cells by killing them using  $\beta$ -galactoside-binding protein ( $\beta$ GBP), an immunomodulatory protein, which is also expressed by CCR4<sup>+</sup> Tregs<sup>5</sup> (24) and shown to induce death of activated T cells (25–27).

## Materials and Methods

**Chemicals and reagents.** Chemicals and reagents were from Sigma, unless specified otherwise. The following antibodies were used: antimouse pan-NK-FITC, antimouse CD27-PE, antimouse Ly-6G and Ly-6C (Gr-1)-FITC, antimouse CD11b-PE, and antimouse F4/80-APC from Caltag; antimouse CD4-FITC, antimouse CD25-PE, and antimouse Foxp3-APC from eBioscience; rabbit anti-mouse CCR4 antibody from Capralogics; and

**Note:** Supplementary data for this article are available at Cancer Research Online (<http://cancerres.aacrjournals.org/>).

P.B. Olkhanud and D. Baatar contributed equally to this article.

**Requests for reprints:** Arya Biragyn, National Institute on Aging, 251 Bayview Boulevard, Suite 100, Baltimore, MD 21224. Phone: 410-558-8680; Fax: 410-558-8284; E-mail: biragyna@mail.nih.gov.


©2009 American Association for Cancer Research.  
doi:10.1158/0008-5472.CAN-08-4619

<sup>5</sup> D. Baatar et al., unpublished data.


Alexa647-conjugated donkey anti-rabbit IgG polyclonal antibody from Invitrogen. Antihuman Gal-1 (AF1152 and BAF1152), anti-CD8-PE antibodies, and CD3<sup>+</sup> T-cell enrichment columns were from R&D Systems, Inc. RPMI 1640, fetal bovine serum (FBS), Dynabeads for CD8, CD25, CD4 isolation and DETACHaBEAD reagent, carboxyfluorescein diacetate succinimidyl ester (CFSE), and ProLong antifade reagent were purchased from Invitrogen Corp. Cells were blocked with Fc block (anti-CD16/32; BD Biosciences). CD25<sup>+</sup>CD4<sup>+</sup> cells were negatively selected using a mouse T-cell CD4 subset column kit (R&D Systems), which was followed with antimouse CD25-PE antibody and anti-PE antibody-conjugated microbeads (Miltenyi Biotec, Inc.), and NK cells were isolated using the NK cell isolation kit (Miltenyi Biotec, Inc.) following manufacturer's instructions. Cell purity was >90%, as assessed by flow cytometry. Human  $\beta$ GBP was previously described (27, 28) and was a generous gift of Dr. Livio Mollucci (King's College London). Production of TARC-PE38, CCL27-PE38, and SLC-PE38, chemokines fused with a truncated form of *Pseudomonas* exotoxin PE38, was reported elsewhere (17, 23). Control nontoxic TARC-Ag protein

consisted of TARC fused with tumor antigen OFA. The proteins were expressed and purified from BL21 (DE3) *Escherichia coli* (Stratagene) with >90% purity.

**Cell lines, mice, and *in vivo* manipulations.** The 4T1 mouse mammary carcinoma cells, human breast cancer MCF-7 and MDA-231, human CCRF-CEM (CEM, CCL-19), and MOLT-4 (CRL-1582) were from American Type Culture Collection; 4T1.2 is a single-cell subclone of 4T1 cells (5). All experiments were performed using 4- to 8-wk-old female BALB/c mice and BALB/c background IL-10 knockout (KO) and nonobese diabetic (NOD)/severe combined immunodeficient (SCID; NOD.CB17-Prkdc<sup>scid</sup>/J; H-2<sup>d</sup>; The Jackson Laboratory) in pathogen-free environment at the National Institute on Aging Animal Facility. Animal care was provided in accordance with the procedures outlined in the Guide for the Care and Use of Laboratory Animals (NIH Publication 86-23, 1985). Mice were challenged s.c. into the fourth mammary gland (pad) with  $1 \times 10^4$  of tumor cells. After 28 d of tumor challenge, lungs were analyzed for metastasis by *ex vivo* injecting India ink through the trachea, which was destained in Fekete's solution to



**Figure 1.** Phenotypic characterization of murine breast 4T1 tumor cells. *A*, expression of TARC (in pg/mL;  $\pm$ SE of triplicate tests, Y axis) in BAL of individual naïve mice (3001 and 3002) and tumor-bearing mice (3507, 3512, and 3522) was assessed by ELISA. To prepare BAL, lungs were washed with 1 mL PBS. *B*, tumor CM, but not control medium (*III*), induces TARC expression in lungs of mice (*I*). Lungs were formalin fixed and paraffin embedded at day 6 after daily single i.p. injections with 0.5 mL tumor CM (*I* and *II*), control medium (*III*), or PBS (*IV*). A representative staining result with anti-TARC antibody (*I*, *III*, and *IV*) or control isotype-matched antibody (*II*) from three mice per group experiment. *C*, CCR4 on the surface of 4T1 tumor cells was stained with anti-CCR4 antibody (black line) and control antibody (gray line). *D*, unlike 4T1-PE and 4T1.2-PE cells, CCR4<sup>+</sup>4T1 tumor cells migrate to TARC (100 ng/mL), but not I-309 (100 ng/mL). Columns, chemotactic index of triplicate experiment; bars, SE. \*,  $P < 0.05$ .



**Figure 2.** The role of CCR4<sup>+</sup> cells in lung metastasis. *Columns*, mean lung metastasis foci of four to five per group of mice experiments; *bars*, SE. *A*, BALB/c mice that were challenged with 4T1, 4T1.2, 4T1-PE, and 4T1.2-PE cells. *B*, 4T1.2 tumor-bearing BALB/c mice that were intratumorally treated with 10  $\mu$ g of TARC-PE38 or control TARC-Ag. *C*, 4T1.2 tumor-bearing BALB/c mice that were depleted of Tregs using anti-CD25 antibody. Control mice were treated with isotype-matched antibody (MOCK). *D*, 4T1.2 tumor-bearing NOD/SCID mice that were transferred with splenocytes or Tregs from naive BALB/c mice or injected with PBS (MOCK). All experiments were reproduced at least thrice. \*,  $P < 0.05$ ; \*\*,  $P < 0.01$ ; \*\*\*,  $P < 0.001$ .

count tumor nodules. NK cells or Tregs were depleted injecting i.v. 50  $\mu$ L anti-asialo GM1 antiserum (Wako) or 500  $\mu$ g i.p. antimouse CD25 antibody or control IgG (PC61, BioXcell) at -1, 3, 10, and 18 d of tumor challenge, respectively. TARC-PE38 and other toxins (5  $\mu$ g) were injected intratumorally or via the tail vein at days 3, 7, and 10 after tumor challenge. BALB/c or IL-10 KO mice  $10^7$  splenocytes or  $10^6$  Tregs alone or mixed with  $10^6$  non-Tregs (as a source of IL-2) or  $2 \times 10^6$  non-Tregs were i.v. injected at days -3, 2, and 7 after tumor challenge to restore metastasis in NOD/SCID mice.

**Detection of chemokine expression in lungs.** TARC and MDC were tested by ELISA with antimouse CCL17 or CCL22 antibodies (R&D Systems, #MAB529 and #MAB4391, respectively) in lung extracts or bronchoalveolar lavage (BAL) washed with 1 mL PBS. Lung cells were isolated by digestion with 1 mg/mL collagenase (Sigma). Paraffin blocks of lung metastasis from three different patients with breast cancer and lung tissues of two healthy humans were from the Department of Pathology, University of Leipzig. Lungs of naive BALB/c mice (i.p. injected 5 d with 0.5 mL of serum-free tumor conditioned medium) or at day 28 after tumor challenge were paraffin embedded. Immunohistochemistry staining was performed as reported elsewhere (29) using the following reagents: human/mouse TARC antibody from Santa Cruz Biotechnology, Inc. and antigen unmasking solution (H-3300), horse serum (S-2000), Avidin-Biotin blocking kit (SP2001), goat IgG (I-5000), biotinylated antigoat IgG (BA-9500), streptavidin-peroxidase and DAB Plus Substrate System from Thermo Scientific. All slides were also counterstained with hematoxylin.

**In vitro manipulations.** Chemotaxis of tumor cells and Tregs were assessed in a 48-well microchemotaxis chamber (NeuroProbe) with a 10- $\mu$ m polycarbonate filter (Osmonics) coated with rat tail collagen type I (BD Biosciences) or using a 24-well tissue transwell plate (5- $\mu$ m pore size, Costar; Corning Life Science), as previously described (30). Results were expressed as mean chemotactic index (number of migrated cells to chemoattractant/number of migrated cells to control media)  $\pm$  SE of three wells. Tumor cell viability was assessed after 48 to 72 h of culture using cell proliferation reagent WST-1 (Roche Applied Science). To test Treg-mediated

apoptosis of NK cells, CFSE-stained NK cells were cultured for 16 h with titrated amounts of either Tregs, non-Tregs, or  $\beta$ GBP in U-bottomed 96-well plates in RPMI with 10% FBS and 1000 units/mL human IL-2. Propidium iodide (PI) and Annexin V-Fluor staining kit (Roche Applied Science) were used to assess apoptosis.

**Statistical analysis.** The results are presented as the mean of triplicates  $\pm$  SD of at least three experiments. Differences were tested using Student's  $t$  test, and a two-sided  $P$  value of  $<0.05$  was considered statistically significant. Data on lymphocyte subsets and breast cancer stage at study entry were collected during Institutional Review Board-approved breast cancer therapy trials conducted at the National Cancer Institute from 1993 to 2007; patients provided informed consent to research sample collection. The absolute number of NK, CD4<sup>+</sup>, and CD8<sup>+</sup> T cells/mm<sup>3</sup> was calculated based upon the percentage of these cells in the lymphocyte gate, the percentage of lymphocytes (defined as CD45<sup>bright</sup>, CD14<sup>-</sup>, SSC<sup>low</sup>), and the WBC counts. Anonymized data were analyzed using Mann-Whitney nonparametric unpaired test to compare lymphocyte subsets from patients at stages II to IV at study entry.

## Results


**Primary tumor induces production of TARC and MDC in the lungs.** We have detected significant amounts of TARC in the BAL of mice that were implanted with 4T1 cells in the mammary pad (Fig. 1A). Because 4T1 and its derivative 4T1.2 cells readily metastasize to lungs (5), this raises an interesting possibility that the primary tumor activated CCR4 ligand (TARC or MDC) production in the lungs to facilitate recruitment of CCR4<sup>+</sup> cells. To test this hypothesis, lungs of naive BALB/c mice were stained for TARC expression after i.p. injections of serum-free conditioned medium from 4T1 cells (tumor CM) or control medium. TARC was significantly up-regulated in lungs of mice that were treated with tumor CM (I), but not control medium (II) or PBS (Fig. 1B, IV). It was

predominantly expressed by epithelial and stromal cells (Fig. 1B, I), but not by infiltrating immune cells (Supplementary Fig. S1). Expression of MDC was also significantly up-regulated in the lung cells of tumor CM-treated mice; it was mostly produced by nonimmune cells (Supplementary Fig. S2A). In concordance, MDC was also produced from *ex vivo* cultured mouse primary fibroblasts when they were treated with tumor CM, but not control medium (Supplementary Fig. S2B). Thus, the primary tumor growing in the mammary gland can activate lungs to produce chemokine ligands for CCR4.

**CCR4 is also expressed on a fraction of breast cancer cells that migrate to TARC.** Next, we have tested whether 4T1 tumor cells (the name that will be used to collectively describe 4T1 and 4T1.2 cells) express CCR4. Indeed, as corroborated by reverse transcription-PCR assay (Supplementary Fig. S3A and B), a low level of CCR4 was detected on the surface of 4T1 tumor cells (Fig. 1C). The receptor expression was functional, as 4T1 tumor cells chemotaxed to TARC (Fig. 1D). Similar low but significant CCR4 expression (11%) was also detected on the surface of human breast cancer MCF7 cells (Supplementary Fig. S3C). Thus, CCR4 might be expressed only on a proportion of 4T1 tumor cells. To test


this possibility, the cells were treated with TARC-PE38 (TARC fusion with a truncated toxin PE38; refs. 17, 23), a formulation that kills CCR4<sup>+</sup> cells without adverse effects on CCR4<sup>-</sup> cells (Supplementary Fig. S4A). Significant cell death was induced by the treatment with TARC-PE38 (Supplementary Fig. S4B), but not with control toxins (SLC-PE38 and CCL27-PE38 which target CCR7 and CCR10, respectively; Supplementary Fig. S4B). However, TARC-PE38 treatment also generated resistant 4T1 and 4T1.2 cells (designated 4T1-PE and 4T1.2-PE, respectively; Supplementary Fig. S4C) that could not chemotax to TARC (Fig. 1D). In conclusion, a proportion of 4T1 tumor cells express functionally active CCR4 and chemotax to TARC.

**CCR4<sup>+</sup>4T1 cells metastasize to lung.** To test the role of CCR4<sup>+</sup> tumor cells in lung metastasis, 4T1 tumor cells and 4T1-PE tumor cells (named to collectively describe 4T1-PE and 4T1.2-PE cells) were transplanted in the mammary pad of syngeneic BALB/c mice. Mice with 4T1 tumor cells succumbed to significant lung metastasis (Fig. 2A; Supplementary Fig. S5) and started dying at 4 weeks after tumor transplantation (data not shown). In contrast, almost no lung metastases were detected in mice challenged with 4T1-PE tumor cells, indicating that the loss of the CCR4<sup>+</sup> subset



**Figure 3.** Tumor induces lung recruitment of CCR4<sup>+</sup> Tregs. *A*, FoxP3<sup>+</sup> cells (*Tregs*), but not NK cells, are significantly increased in the lungs of mice i.p. treated with tumor CM (as in Fig. 1B). In contrast, both populations were increased in spleens of tumor CM-treated mice. *Columns*, change in absolute numbers of cells compared with PBS-treated group of three mice per group experiment repeated twice; *bars*, SE. *B*, Tregs present in the lungs of NOD/SCID mice after transfer with BALB/c Tregs, splenocytes, or non-Tregs or splenocytes from IL-10-deficient mice (*IL-10 KO*) at day 28 after tumor challenge. *Columns*, mean proportion of CD4<sup>+</sup> cells (*left*) and mean of lung metastasis (*right*) of four mice per group experiment; *bars*, SE. *C*, CCR4 expression on Tregs (*left*) and NK cells (*right*) is shown after staining with anti-CCR4 antibody (*gray area*) and control antibody (*open area*), respectively. *D*, Tregs in Fig. 2D chemotax to TARC (100 ng/mL). They also migrate to extracts from lungs (*Lung ext.*) of mice treated with tumor CM (as in Fig. 1B) using CCR4. TARC was added in upper wells of chemotactic chamber to abrogate chemotaxis. *Columns*, chemotactic index of triplicate experiment repeated thrice; *bars*, SE. \*, *P* < 0.05; \*\*, *P* < 0.01; \*\*\*, *P* < 0.001.

**Figure 4.** The role of NK cells in lung metastasis. **A**, BALB/c splenocytes pretreated with TARC-Ag or mock (PBS) restore lung metastasis of 4T1.2 tumor cells in NOD/SCID mice, which is abrogated by 1 h TARC-PE38 pretreatment of the splenocytes prior the adoptive transfer (TARC-PE38). Control mice (No Splenocytes) were only challenged with 4T1.2 tumor. Columns, mean of lung metastasis of five mice per group experiment repeated thrice; bars, SE. **B**, NK cells protect lungs of NOD/SCID mice from metastasis of 4T1.2 tumor cells. Tumor-bearing mice were i.v. treated with anti-asialo GM1. Control mice were injected with rabbit sera (IgG) or with PBS. Columns, mean of lung metastasis of four mice per group experiment reproduced twice; bars, SE. **C**, the numbers of NK cells and Tregs inversely correlate in tumor-bearing BALB/c mice. Tregs were depleted as in Fig. 2C. Columns, mean proportion (%) of Tregs and NK cells in PB, lymph nodes (LN), and spleens (SP) of four mice per group experiment; bars, SE. **D**, the transfer of BALB/c Tregs or BALB/c splenocytes significantly reduces NK cell numbers in PB of tumor-bearing NOD/SCID mice. Control mice were transferred with BALB/c non-Tregs or splenocytes from IL-10-deficient mice (IL-10 KO Splenocytes). Cells were analyzed by fluorescence-activated cell sorting after staining for Pan-NK, CD27, and CD25<sup>High</sup> CD4<sup>+</sup> markers. \*,  $P < 0.05$ ; \*\*,  $P < 0.01$ ; \*\*\*,  $P < 0.001$ .



abrogates lung metastasis. Specifically, 4T1.2-PE challenged mice were completely free of lung metastasis (Fig. 2A; Supplementary Fig. S5). This is not due to *in vitro* selection-introduced artifacts of 4T1-PE cells, as lung metastasis of parental 4T1 tumors was also significantly reduced by *in vivo* intratumoral treatments with TARC-PE38 ( $P < 0.01$ ; Fig. 2B). In contrast, treatments with control TARC-Ag (a nontoxic formulation that also signals through CCR4; ref. 17) failed to reduce lung metastasis (Fig. 2B). In conclusion, lung metastases are caused by CCR4<sup>+</sup> 4T1 tumor cells.

**Tregs are required for lung metastasis.** Tregs also express CCR4 and infiltrate lungs and tumors producing TARC/MDC (13, 18, 31). Thus, they could also be recruited in the lungs of 4T1-bearing mice to protect metastasis through suppression of antitumor responses. To test this possibility, 4T1.2 tumor-bearing BALB/c mice were depleted of Tregs by systemic treatment with PC61 antibody. The mice treated with PC61, but not with isotype-matched control antibody (mock), were almost completely free of lung metastasis (anti-CD25 antibody; Fig. 2C). Thus, although some effector T cells could also be depleted, the data indicate that Tregs were required for lung metastasis of 4T1 tumor cells. To confirm this, we have transplanted 4T1.2 cells into T and B cell-deficient NOD/SCID mice. In these mice, the 4T1.2 tumor growth was not affected at the primary challenge site (mammary pad; data not shown), yet the tumor cells were unable to metastasize. The lack of metastasis is not due to the inability of the tumor to activate lungs, as their BALs had readily detectable TARC and MDC (Supplementary Fig. S6). In contrast, lung metastasis was restored in NOD/SCID mice after transfer of splenocytes from naive BALB/c mice (Fig. 2D). Similarly, lung metastases were also restored after transfer of Tregs (CD25<sup>+</sup>CD4<sup>+</sup>) either alone or in combination with non-Tregs (CD25<sup>+</sup>CD4<sup>+</sup>, as source of IL-2; Fig. 2D). The transfer of

the same number of CD25<sup>-</sup>CD4<sup>+</sup> T cells did not restore metastasis and only sporadically yielded a few metastatic foci (non-Tregs; Fig. 2D).

Lungs of tumor-bearing mice (data not shown) or mice i.p. injected with tumor CM, but not control medium, contained significantly enhanced amounts of Foxp3<sup>+</sup> Tregs ( $P > 0.05$ ; Fig. 3A). Similarly, in the lungs of tumor-bearing NOD/SCID mice, their numbers were increased and maintained for 4 weeks only after transfer of Tregs and splenocytes (Fig. 3B). Tregs were predominantly CCR4<sup>+</sup> (Fig. 3C) and chemotaxed to TARC (Fig. 3D; Supplementary Fig. S7) and to lung extracts from the mice injected with tumor CM using TARC (as the chemotaxis was completely abolished when TARC was present in the upper wells of the chemotaxis chamber,  $P < 0.001$ ; Fig. 3D). Thus, as reported for inflamed lungs (13, 18, 31), tumor may also facilitate lung recruitment of CCR4<sup>+</sup> Tregs to support lung metastasis. In support, the pretreatment of BALB/c splenocytes or Tregs with TARC-PE38, but not control TARC-Ag, prior adoptive transfer almost completely abolished the ability of BALB/c splenocytes (Fig. 4A) or Tregs (Supplementary Fig. S8) to restore lung metastasis in NOD/SCID mice.

**Tregs promote lung metastasis by regulating antitumor NK cells.** Tregs primarily regulate T-cell responses and promote escape from immune surveillance (13, 14, 32). However, 4T1 tumors failed to metastasize in mice with impaired T cells (NOD/SCID mice) in the absence of Tregs, and depletion of CD4<sup>+</sup> and CD8<sup>+</sup> T cells did not affect lung metastasis of 4T1 tumors in BALB/c mice (Supplementary Fig. S9), indicating that lung metastasis was controlled by other immune cells. Because NK cells can exhibit antimetastatic activity (33) and can be controlled by Tregs (34), the inability of 4T1 cells to metastasize in NOD/SCID mice might be due to the loss of Tregs. Indeed, depletion of NK cells alone rendered NOD/SCID

mice susceptible to metastasis drastically enhancing 4T1.2 tumor foci in the lungs (Fig. 4B). Because the transfer of Tregs in NOD/SCID mice (Figs. 2D) or depletion of Tregs in BALB/c mice (Fig. 2C) restored or abolished lung metastasis of 4T1 tumors, respectively, these data taken together indicate that Tregs regulated NK cells to support lung metastasis. In fact, their numbers were inversely correlated in peripheral blood (PB) of tumor-bearing mice, and the PC61 antibody-mediated depletion of Tregs resulted in a significant increase of NK cell numbers (Fig. 4C). The NK cell numbers were significantly reduced in PB of NOD/SCID mice that succumbed to lung metastasis due to the adoptive transfer of BALB/c Tregs or splenocytes (Fig. 4D). In control mice treated with control antibody (IgG; Fig. 4C) or transfused with non-Tregs (Fig. 4D), the NK cell numbers were not changed. Tregs, but not NK cells, were also increased in the lungs of tumor CM-treated mice (Fig. 3A).


The inverse correlation between Tregs and NK cell numbers also suggests that Tregs may directly affect viability of NK cells. Indeed, Tregs induced significant NK apoptosis when they were co-cultured *in vitro* (Fig. 5A). However, to do this efficiently, the proportion of Tregs had to be at least 4-fold higher (4:1; Fig. 5A), as they were by themselves killed by NK cells if mixed at lower doses (1:1; Fig. 5B). This cytotoxic interaction between Tregs and NK cells is specific, as no reciprocal killing was detected when non-Tregs were cocultured with NK cells (Fig. 5A and B). Although the purpose of the current study was not to elucidate the mechanisms of this killing, Tregs seem to use a previously unknown pathway involving the  $\beta$ GBP. Freshly isolated Tregs, but not non-Tregs, abundantly secreted  $\beta$ GBP (data not shown), and micromole amounts of recombinant  $\beta$ GBP induced significant apoptosis of NK cells, but not nonactivated T cells (Fig. 5C). Of note, these amounts are several logs below the "natural" cytotoxic doses of  $\beta$ GBP (35).


**The CCR4<sup>-</sup> targeting strategies can efficiently control lung metastasis.** Taken together, these data suggest that TARC recruits CCR4<sup>+</sup> tumor cells together with CCR4<sup>+</sup> Tregs to protect them from NK cells. Therefore, we hypothesized that lung metastasis may be controlled by strategies that target CCR4. To test this, 4T1 tumor-bearing BALB/c mice were injected i.v. with 5  $\mu$ g TARC-PE38, a total of three times. In parallel, separate groups of mice were injected with 5  $\mu$ g control TARC-Ag, with toxin that targeted CCR10 (CCL27-PE38), or with 500  $\mu$ g of either anti-CD25 antibody or control IgG. Whereas control treatments, such as CCL27-PE38 (Supplementary Fig. S10), or TARC-Ag and control IgG did not affect lung metastasis (Fig. 5D), lungs of the mice injected with TARC-PE38 or anti-CD25 antibody had significantly less metastatic foci (Fig. 5D), indicating that the strategies that eliminate CCR4-expressing cells can reduce lung metastasis as efficiently as antibody-mediated depletion of Tregs.

## Discussion

The role of chemokine receptors in cancer metastasis remains undefined. Even in the highly metastatic murine 4T1 breast cancer model, the role of chemokines and chemokine receptors has been thought to be indirect and associated with recruitment of other cells (36). Here, we show that 4T1 tumor is actually heterogeneous and that lung metastasis is only mediated by CCR4<sup>+</sup> tumor cells. CCR4 has never been linked with breast cancer or lung metastasis, and the fact that a small but significant proportion of human breast cancer MCF7 cells also expressed CCR4 indicates that this was not an isolated case. Nevertheless, CCR4 expression alone was not sufficient in the absence of an active participation of host immune cells. 4T1 tumor is known to expand Gr1<sup>+</sup> MDSCs through production of GM-CSF, IL-1 $\beta$ , IL-6, and transforming

**Figure 5.** Tregs can directly kill NK cells. Purified Tregs or non-Tregs were incubated with CFSE-labeled NK cells at indicated ratio before staining with PI. Columns, proportion (%) of apoptotic NK cells (PI<sup>+</sup>CFSE<sup>+</sup>, A) and Tregs (PI<sup>+</sup>CFSE<sup>-</sup>, B) of triplicate experiments; bars, SE. C, effects of  $\beta$ GBP on NK cells (filled circles) and T cells (open circles). Points, proportion of apoptotic cells (%; PI<sup>+</sup> of triplicate experiment); bars, SE. Experiments were repeated at least thrice. D, lung metastasis can be controlled by targeting CCR4<sup>+</sup> cells. 4T1.2 tumor-bearing mice were i.v. treated with TARC-PE38 or TARC-Ag, or control TARC-Ag or mock (PBS). Columns, mean lung metastasis; bars, SE. Experiments were reproduced thrice. \*,  $P < 0.05$ ; \*\*,  $P < 0.01$ ; \*\*\*,  $P < 0.001$ .





Downloaded from http://aacrjournals.org/cancerres/article-pdf/69/14/5996/2612635/5996.pdf by guest on 23 May 2024

**Figure 6.** A, NK cells are reduced in PB of breast cancer patients with the advanced/metastatic disease. The data are from nonparametric Mann-Whitney analysis of previously untreated 73 breast cancer patients. Columns, T-cell (CD3<sup>+</sup>) and NK cell counts in PB of patients with stage II and advanced disease (stages III and IV). B, schema that summarizes the finding. Primary breast cancer is heterogeneous; it consists of at least CCR4<sup>+</sup> and CCR4<sup>-</sup> cells (1). TARC is induced in lungs by the primary tumor growing in mammary pad (open arrows, 2). This allows CCR4<sup>+</sup> tumors to leave the primary site (3) and metastasize to lungs (2). However, the cells are efficiently killed by NK cells (6), unless they migrate together with their protectors, CCR4<sup>+</sup> Tregs (4). Tregs inactivate NK cells using  $\beta$ GBP (5). However, Tregs can be also killed by NK cells (7), if they are present at lower numbers. C, immunohistochemistry staining of mouse (I–III) and human (IV–VI) lungs with 4T1 tumors (II and III) and human breast cancer (V and VI). Control antibody (III and VI) or anti-TARC antibody (II and V) stainings of tumor-bearing lungs or normal tumor-free lungs (I and IV) of mice and human, respectively.

growth factor- $\beta$  (6, 7, 37), which directly or indirectly impair immune responses and support survival and metastasis of 4T1 tumor cells (8, 10). However, MDSCs may not be primary contributors of lung metastasis, because they were comparably well expanded

in NOD/SCID mice that did not support tumor metastasis, and the depletion of Tregs also reduced the proportion of Gr1<sup>+</sup> and GR1<sup>int</sup>/F4/80<sup>+</sup> cells in tumor-bearing BALB/c mice (data not shown). Our data suggest that CCR4<sup>+</sup> Tregs facilitate lung metastasis of 4T1

tumors. Although the methods used here could also affect non-Treg T cells, we do not think that non-Treg cells helped lung metastasis. First, the depletion of CD4<sup>+</sup> or CD8<sup>+</sup> T cells did not affect lung metastasis in BALB/c mice. Second, the transfer of non-Treg T cells did not restore lung metastasis in nonpermissive NOD/SCID mice. In contrast, only depletion of Tregs could abrogate lung metastasis of 4T1 tumors in BALB/c mice. Moreover, the inability of 4T1 tumors to metastasize in NOD/SCID mice was reversed, and lung metastasis ability was restored by adoptive transfer of Tregs. This restoration failed if Tregs were pretreated with TARC-PE38 before the transfer that specifically killed CCR4<sup>+</sup> cells. These results are in concordance with our previous report that Tregs are efficient suppressors of T-cell responses (17).

Tregs adversely affect NK cell-mediated cancer therapy (34), presumably by suppressing NK cell activity (38) or NK cell maturation (39) or through inhibition of NK cell and dendritic cell cross-talk (40). In concordance, our data indicate that Treg can also kill NK cells to protect lung metastasis. To do this, they use  $\beta$ GBP, a lectin-type immunomodulatory protein, which was shown to be abundantly expressed by Tregs (24), specifically by CCR4<sup>+</sup>Tregs.<sup>6</sup> At present, we can only speculate that the Treg-mediated killing of NK cells has probably occurred in the lungs. Unlike PB and lungs, no inverse correlation between Treg and NK cell numbers were detected in the secondary lymphoid organs of tumor CM-treated or tumor-bearing mice (Figs. 3A and 4C). Because 4T1 tumor closely reflects human metastatic breast cancer, it is tempting to speculate that Tregs may also regulate NK cells facilitating human cancer progression, particularly in advanced disease when metastasis is prevalent. In support, using a retrospective analysis of lymphocyte subsets in 73 previously untreated patients with breast cancer, we have found that NK and T-cell levels were significantly reduced in patients with metastatic stage IV disease compared with those with nonmetastatic stage II tumors (Mann-Whitney nonparametric comparison for NK cells,  $P < 0.004$ , Fig. 6A). Similar reduced NK cell counts and increased proportion of Tregs were also observed by others in PB of cancer patients with the advanced stages of head and neck squamous cell carcinoma (41). The decrease in numbers of tumor-infiltrating CD8<sup>+</sup> and CD56<sup>+</sup> cells was also associated with a unfavorable clinical course of patients with Hodgkin's disease and colorectal cancer (42, 43). These observations could presumably be explained either by the ability of Tregs to control the generation of mature NK cells (39) or by our finding that Tregs were, in fact, able to kill NK cells.

Overall, our data (summarized in Fig. 6B) show that lung metastasis of breast cancer 4T1 cells is an active multistep process; on one hand, it requires CCR4 expression on the tumor cells to home into lungs that are producing TARC or MDC. In fact, the primary tumor growing in the mammary gland actively prepares its

metastasis target site through induction of TARC and MDC expression in lung. Although the mechanism of this remote induction of chemokine production remains unknown, lungs could be activated by a wide range of tumor-produced soluble factors that induce the mobilization and activation of MDSCs, such as tumor necrosis factor- $\alpha$ , IL-6, and GM-CSF (6, 7, 37). However, even in the absence of this, TARC/MDC may be produced during pulmonary inflammation and various allergic diseases (22, 44), which would periodically provide chemotactic stimuli for tumors. Despite this, lung metastasis cannot be established without the active participation of immune cells. As CCR4<sup>+</sup> Tregs infiltrate inflamed lungs (22), we define CCR4<sup>+</sup> Tregs as the required subset that infiltrate metastatic lungs. In support, FoxP3<sup>+</sup> cell count was significantly increased in the lungs of tumor-bearing mice or mice i.p. injected with tumor CM. In addition, their long-term presence (at least 4 weeks) in the lungs of NOD/SCID mice was only detected in the mice that restored lung metastasis after adoptive transfer BALB/c Tregs, but not non-Tregs. Importantly, both the presence of Tregs and the support of metastasis in NOD/SCID mice were abolished if CCR4<sup>+</sup> Tregs were killed by pretreatment with TARC-PE38 before transfer.

TARC/MDC expression is often correlated with a poor disease prognosis for cancer patients (1, 45). In concordance, both murine and human breast cancer expressed TARC, as shown by immunohistochemistry staining of lungs with metastatic 4T1 tumor (II) and several (three of three) patients with breast cancer (Fig. 6 C, V). Although the biological meaning of this remains unknown, it is tempting to speculate that, as in human ovarian cancer (13), this is to recruit CCR4<sup>+</sup> Tregs and escape from immune surveillance. Taken together, our data suggest that CCR4 is also an important metastasis-associated receptor. Thus, strategies that target CCR4 (using TARC-PE38 treatment) or Tregs (using the antibody-mediated depletion of Tregs) would be expected to have significant benefit in the control of lung metastasis, as they would shift responses toward protective antitumor innate and adaptive immune responses. The restoration of NK activity is often a sign of better cumulative survival outcome in cancer patients (46, 47).

## Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

## Acknowledgments

Received 12/8/08; revised 3/18/09; accepted 4/11/09; published OnlineFirst 6/30/09.

**Grant support:** Intramural Research Program of the National Institute on Aging (NIA), NIH.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

We thank Dr. Dan Longo (NIA/NIH) for helpful comments and suggestions; Ana Lustig (NIA/NIH) for critical reading of the manuscript; Drs. Dennis Taub, Ashani Weeraratna (NIA/NIH), and Fred E. Indig (NIA) for help with immunohistochemistry and confocal microscopy imaging; and Dr. Lars-Christian Horn (University of Leipzig) for providing the human lung tissue slides.

<sup>6</sup> D. Baatar et al., unpublished data.

## References

- Muller A, Homey B, Soto H, et al. Involvement of chemokine receptors in breast cancer metastasis. *Nature* 2001;410:50–6.
- Rubie C, Frick VO, Wagner M, et al. Enhanced expression and clinical significance of CC-chemokine MIP-3  $\alpha$  in hepatocellular carcinoma. *Scand J Immunol* 2006;63:468–77.
- Balkwill F. Cancer and the chemokine network. *Nat Rev Cancer* 2004;4:540–50.
- Gunther K, Leier J, Henning G, et al. Prediction of lymph node metastasis in colorectal carcinoma by expression of chemokine receptor CCR7. *Int J Cancer* 2005;116:726–33.
- Lelekakis M, Moseley JM, Martin TJ, et al. A novel orthotopic model of breast cancer metastasis to bone. *Clin Exp Metastasis* 1999;17:163–70.
- DuPre SA, Redelman D, Hunter KW, Jr. The mouse mammary carcinoma 4T1: characterization of the cellular landscape of primary tumors and metastatic tumour foci. *Int J Exp Pathol* 2007;88:351–60.
- Danna EA, Sinha P, Gilbert M, Clements VK, Pulaski BA, Ostrand-Rosenberg S. Surgical removal of primary tumor reverses tumor-induced immunosuppression despite the presence of metastatic disease. *Cancer Res* 2004;64:2205–11.



8. Serafini P, De SC, Marigo I, et al. Derangement of immune responses by myeloid suppressor cells. *Cancer Immunol Immunother* 2004;53:64–72.
9. DuPre SA, Hunter KW, Jr. Murine mammary carcinoma 4T1 induces a leukemoid reaction with splenomegaly: association with tumor-derived growth factors. *Exp Mol Pathol* 2007;82:12–24.
10. Huang B, Pan PY, Li Q, et al. Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. *Cancer Res* 2006;66:1123–31.
11. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor  $\alpha$ -chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. *J Immunol* 1995;155:1151–64.
12. Ishida T, Utsunomiya A, Iida S, et al. Clinical significance of CCR4 expression in adult T-cell leukemia/lymphoma: its close association with skin involvement and unfavorable outcome. *Clin Cancer Res* 2003;9:3625–34.
13. Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. *Nat Med* 2004;10:942–9.
14. Woo EY, Yeh H, Chu CS, et al. Cutting edge: regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. *J Immunol* 2002;168:4272–6.
15. Beyer M, Kochanek M, Darabi K, et al. Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. *Blood* 2005;106:2018–25.
16. Lloyd CM, Rankin SM. Chemokines in allergic airway disease. *Curr Opin Pharmacol* 2003;3:443–8.
17. Baatar D, Olkhanud P, Sumitomo K, Taub D, Gress R, Biragyn A. Human peripheral blood T regulatory cells (Tregs), functionally primed CCR4+ Tregs and unprimed CCR4-Tregs, regulate effector T cells using FasL. *J Immunol* 2007;178:4891–900.
18. Iellem A, Mariani M, Lang R, et al. Unique chemotactic response profile and specific expression of chemokine receptors CCR4 and CCR8 by CD4(+)/CD25(+) regulatory T cells. *J Exp Med* 2001;194:847–53.
19. Inngjerdingen M, Damaj B, Maghazachi AA. Human NK cells express CC chemokine receptors 4 and 8 and respond to thymus and activation-regulated chemokine, macrophage-derived chemokine, and I-309. *J Immunol* 2000;164:4048–54.
20. Meyer EH, Wurbel MA, Staton TL, et al. iNKT cells require CCR4 to localize to the airways and to induce airway hyperreactivity. *J Immunol* 2007;179:4661–71.
21. Johansson C, Ahlstedt I, Furubacka S, Johnsson E, Agace WW, Quiding-Jarbrink M. Differential expression of chemokine receptors on human IgA+ and IgG+ B cells. *Clin Exp Immunol* 2005;141:279–87.
22. Jacobsen EA, Ochkur SI, Pero RS, et al. Allergic pulmonary inflammation in mice is dependent on eosinophil-induced recruitment of effector T cells. *J Exp Med* 2008;205:699–710.
23. Baatar D, Olkhanud P, Newton D, Sumitomo K, Biragyn A. CCR4-expressing T cell tumors can be specifically controlled via delivery of toxins to chemokine receptors. *J Immunol* 2007;179:1996–2004.
24. Garin MI, Chu CC, Golshayan D, Cernuda-Morollon E, Wait R, Lechler RI. Galectin-1: a key effector of regulation mediated by CD4+CD25+ T cells. *Blood* 2007;109:2058–65.
25. Ravatn R, Wells V, Nelson L, Vettori D, Mallucci L, Chin KV. Circumventing multidrug resistance in cancer by  $\beta$ -galactoside binding protein, an antiproliferative cytokine. *Cancer Res* 2005;65:1631–4.
26. Novelli F, Allione A, Wells V, Forni G, Mallucci L. Negative cell cycle control of human T cells by  $\beta$ -galactoside binding protein ( $\beta$ GBP): induction of programmed cell death in leukaemic cells. *J Cell Physiol* 1999;178:102–8.
27. Allione A, Wells V, Forni G, Mallucci L, Novelli F.  $\beta$ -galactoside-binding protein ( $\beta$ GBP) alters the cell cycle, up-regulates expression of the  $\alpha$ - and  $\beta$ -chains of the IFN- $\gamma$  receptor, and triggers IFN- $\gamma$ -mediated apoptosis of activated human T lymphocytes. *J Immunol* 1998;161:2114–9.
28. Wells V, Mallucci L. Identification of an autocrine negative growth factor: mouse  $\beta$ -galactoside-binding protein is a cytostatic factor and cell growth regulator. *Cell* 1991;64:91–7.
29. Almanzar G, Olkhanud PB, Bodogai M, et al. Sperm-Derived SPANX-B Is a Clinically Relevant Tumor Antigen That Is Expressed in Human Tumors and Readily Recognized by Human CD4+ and CD8+ T Cells. *Clin Cancer Res*. 2009;15:1954–63.
30. Falk W, Goodwin RHJ, Leonard EJ. A 48-well microchemotaxis assembly for rapid and accurate measurement of leukocyte migration. *J Immunol Methods* 1980;33:239–47.
31. Saito K, Torii M, Ma N, et al. Differential regulatory function of resting and preactivated allergen-specific CD4+ CD25+ regulatory T cells in Th2-type airway inflammation. *J Immunol* 2008;181:6889–97.
32. Aandahl EM, Michaelsson J, Moretto WJ, Hecht FM, Nixon DF. Human CD4+ CD25+ regulatory T cells control T-cell responses to human immunodeficiency virus and cytomegalovirus antigens. *J Virol* 2004;78:2454–9.
33. Zheng LM, Ojcius DM, Garaud F, et al. Interleukin-10 inhibits tumor metastasis through an NK cell-dependent mechanism. *J Exp Med* 1996;184:579–84.
34. Smyth MJ, Teng MW, Swann J, Kyriarisoudis K, Godfrey DI, Hayakawa Y. CD4+CD25+ T regulatory cells suppress NK cell-mediated immunotherapy of cancer. *J Immunol* 2006;176:1582–7.
35. Camby I, Le MM, Lefranc F, Kiss R. Galectin-1: a small protein with major functions. *Glycobiology* 2006;16:137–57R.
36. van Deventer HW, O'Connor W, Jr., Brickey WJ, Aris RM, Ting JP, Serody JS. C-C chemokine receptor 5 on stromal cells promotes pulmonary metastasis. *Cancer Res* 2005;65:3374–9.
37. Sinha P, Clements VK, Ostrand-Rosenberg S. Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease. *J Immunol* 2005;174:636–45.
38. Barao I, Hanash AM, Hallett W, et al. Suppression of natural killer cell-mediated bone marrow cell rejection by CD4+CD25+ regulatory T cells. *Proc Natl Acad Sci U S A* 2006;103:5460–5.
39. Giroux M, Yurchenko E, St-Pierre J, Piccirillo CA, Perreault C. T regulatory cells control numbers of NK cells and CD8 $\alpha$ + immature dendritic cells in the lymph node paracortex. *J Immunol* 2007;179:4492–502.
40. Terme M, Chaput N, Combadiere B, Ma A, Ohteki T, Zitvogel L. Regulatory T cells control dendritic cell/NK cell cross-talk in lymph nodes at the steady-state by inhibiting CD4+ self-reactive T cells. *J Immunol* 2008;180:4679–86.
41. Bose A, Chakraborty T, Chakraborty K, Pal S, Baral R. Dysregulation in immune functions is reflected in tumor cell cytotoxicity by peripheral blood mononuclear cells from head and neck squamous cell carcinoma patients. *Cancer Immun* 2008;8:10.
42. varo-Naranjo T, Lejeune M, Salvado-Usach MT, et al. Tumor-infiltrating cells as a prognostic factor in Hodgkin's lymphoma: a quantitative tissue microarray study in a large retrospective cohort of 267 patients. *Leuk Lymphoma* 2005;46:1581–91.
43. Milasiene V, Stratilatovas E, Norkiene V, Jonusauskaite R. Lymphocyte subsets in peripheral blood as prognostic factors in colorectal cancer. *J BUON* 2005;10:261–4.
44. Gonzalo JA, Pan Y, Lloyd CM, et al. Mouse monocyte-derived chemokine is involved in airway hyperreactivity and lung inflammation. *J Immunol* 1999;163:403–11.
45. White ES, Flaherty KR, Carskadon S, et al. Macrophage migration inhibitory factor and CXC chemokine expression in non-small cell lung cancer: role in angiogenesis and prognosis. *Clin Cancer Res* 2003;9:853–60.
46. Imai K, Matsuyama S, Miyake S, Suga K, Nakachi K. Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population. *Lancet* 2000;356:1795–9.
47. Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. *Science* 2002;295:2097–100.